Subscribe: pubmed: J Clin Oncol[jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0xy0toGbHxILuEPGwp_ae_cVH56FyeEC_BtpcMo4J85
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
authors  cancer  clin oncol  clin  genetic testing  genetic  oncol  patients  pca  pmid pubmed  pmid  pubmed process  pubmed  testing 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: pubmed: J Clin Oncol[jour]

pubmed: J Clin Oncol[jour]



NCBI: db=pubmed; Term=J Clin Oncol[jour]



 



ERRATUM.

ERRATUM.

J Clin Oncol. 2016 Nov 10;34(32):3952

Authors:

PMID: 29236620 [PubMed - in process]




Aspirin, Colorectal Cancer, and Cause of Death: A Complex Landscape.

Aspirin, Colorectal Cancer, and Cause of Death: A Complex Landscape.

J Clin Oncol. 2017 Feb 10;35(5):568-569

Authors: Løberg M, Holme Ø, Kalager M

PMID: 29236619 [PubMed - in process]




Reply to K.R. Hoffman.

Reply to K.R. Hoffman.

J Clin Oncol. 2017 Feb 10;35(5):567-568

Authors: Cortes JE, Hochhaus A

PMID: 29236618 [PubMed - in process]




How Does One Decide Which Tyrosine Kinase Inhibitor To Use for the Initial Treatment of Chronic-Phase Chronic Myeloid Leukemia?

How Does One Decide Which Tyrosine Kinase Inhibitor To Use for the Initial Treatment of Chronic-Phase Chronic Myeloid Leukemia?

J Clin Oncol. 2017 Feb 10;35(5):567

Authors: Hoffman KR

PMID: 29236617 [PubMed - in process]




Reply to M. Løberg et al.

Reply to M. Løberg et al.

J Clin Oncol. 2017 Feb 10;35(5):569-571

Authors: Bains SJ, Mahic M, Myklebust TÅ, Småstuen MC, Yaqub S, Dørum LM, Bjørnbeth BA, Møller B, Brudvik KW, Taskén K

PMID: 29236616 [PubMed - in process]




ERRATA.

ERRATA.

J Clin Oncol. 2016 Nov 20;34(33):4059

Authors:

PMID: 29236598 [PubMed - in process]




Immunochemotherapy, the New Standard of Care for Primary CNS Lymphoma: However, Which One?

Immunochemotherapy, the New Standard of Care for Primary CNS Lymphoma: However, Which One?

J Clin Oncol. 2016 Nov 20;34(33):4056-4057

Authors: Chamberlain MC

PMID: 29236597 [PubMed - in process]




Genomic Assays and Individualized Treatment of Ductal Carcinoma In Situ in the Era of Value-Based Cancer Care.

Genomic Assays and Individualized Treatment of Ductal Carcinoma In Situ in the Era of Value-Based Cancer Care.

J Clin Oncol. 2016 Nov 20;34(33):3953-3955

Authors: Leonard KL, Wazer DE

PMID: 29236596 [PubMed - in process]




ERRATA.

ERRATA.

J Clin Oncol. 2016 Nov 20;34(33):4059

Authors:

PMID: 29236595 [PubMed - in process]




Reply to M.C. Chamberlain.

Reply to M.C. Chamberlain.

J Clin Oncol. 2016 Nov 20;34(33):4057

Authors: Glass J, Werner-Wasik M, Mehta MP

PMID: 29236594 [PubMed - in process]




Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

J Clin Oncol. 2017 Dec 13;:JCO2017741173

Authors: Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG

Abstract
Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.

PMID: 29236593 [PubMed - as supplied by publisher]




Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer.

Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer.

J Clin Oncol. 2017 Dec 13;:JCO2017744771

Authors: Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, Akerley W, Kokeny KE

Abstract
Purpose Although several feasibility studies have demonstrated the safety of adjuvant concurrent chemoradiotherapy (CRT) for locally advanced or incompletely resected non-small-cell lung cancer (NSCLC), it remains uncertain whether this approach is superior to sequential chemotherapy followed by postoperative radiotherapy (C→PORT). We sought to determine the most effective treatment sequence. Patients and Methods Using the National Cancer Database, we selected two cohorts of patients with nonmetastatic NSCLC who had received at least a lobectomy followed by multiagent chemotherapy and radiotherapy; cohort one included patients with R0 resection and pN2 disease, whereas cohort two included patients with R1-2 resection regardless of nodal status. Overall survival (OS) was examined using a propensity score-matched analysis with a shared frailty Cox regression. Results A total of 747 patients in cohort one and 277 patients in cohort two were included, with a median follow-up of 32.8 and 27.9 months, respectively. The median OS was 58.8 months for patients who received C→PORT versus 40.4 months for patients who received CRT in cohort one (log-rank P < .001). For cohort two, the median OS was 42.6 months for patients who received C→PORT versus 38.5 months for patients who received CRT (log-rank P = .42). After propensity score matching, C→PORT remained associated with improved OS compared with CRT in cohort one (hazard ratio, 1.35; P = .019), and there was no statistical difference in OS between the sequencing groups for cohort two (hazard ratio, 1.35; P = .19). Conclusion Patients with NSCLC who undergo R0 resection and are found to have pN2 disease have improved outcomes when adjuvant chemotherapy is administered before, rather than concurrently with, radiotherapy. For patients with positive margins after surgery, there is not a clear association between treatment sequencing and survival.

PMID: 29236592 [PubMed - as supplied by publisher]




The Raven.

The Raven.

J Clin Oncol. 2017 Dec 13;:JCO2017763458

Authors: Steensma DP

PMID: 29236583 [PubMed - as supplied by publisher]




Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data.

Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data.

J Clin Oncol. 2017 Dec 13;:JCO2017761759

Authors: Booth CM, Karim S, Peng Y, Siemens DR, Brennan K, Mackillop WJ

PMID: 29236572 [PubMed - as supplied by publisher]




Soaring Cost of Cancer Treatment: Moving Beyond Sticker Shock.

Soaring Cost of Cancer Treatment: Moving Beyond Sticker Shock.

J Clin Oncol. 2017 Dec 13;:JCO2017760488

Authors: Gross CP, Gluck AR

PMID: 29236571 [PubMed - as supplied by publisher]




Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

J Clin Oncol. 2017 Dec 13;:JCO2017758193

Authors: Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM

PMID: 29236570 [PubMed - as supplied by publisher]